anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine. SUBSTANCE: method involves applying heparin treatment of vascular bed to prevent thrombus formation, as soon as spinal artery surgical access and mobilization are carried out according to generally accepted rules of vascular surgery, that is, by intravenous administering 5000 units of heparin that starts being active in 5 min in the average. Then, 1 ml of dalargin is administered 3 min later, diluted with 2-3 ml of physiological salt solution. 2 min later, the time neuropeptide starts its action, blood circulation in the artery under operation is to be stopped by applying vascular forceps or special kind of spring clips to the proximal and distal portions of the vessel. Then, required kind of restorative operation is carried out for the main pathogenic factor, causing brain ischemia, to be removed. EFFECT: enhanced effectiveness of treatment.
Older adults, as well as those with certain neurological disorders, may compensate for poor neural control of postural stability by widening their base of foot support while walking. However, the extent to which this wide-based gait improves postural stability or affects postural control strategies has not been explored. People with idiopathic Parkinson's disease (iPD, n = 72), frontal gait disorders (FGD, n = 16), and healthy older adults (n = 32) performed walking trials at their preferred speed over an 8-m-long, instrumented walkway. People with iPD were tested in their OFF medication state. Analyses of covariance were performed to determine the associations between stride width and measures of lateral stability control. People with FGD exhibited a wide-based gait compared to both healthy older adults and iPD. An increased stride width was associated with an increase in lateral margin of stability in FGD. Unlike healthy older adults or iPD, people with FGD did not externally rotate their feet (toe-out angle) or shift their center of pressure laterally to aid lateral dynamic stability during walking but slowed their gait instead to increase stability. By adopting a slow, wide-based gait, people with FGD take advantage of the passive, pendular mechanics of walking.
Embodiments may include a composition for oral drug delivery. The composition may include a physiologically active substance, a carrier compound, a mucoadhesive compound, and a permeation enhancer. The physiologically active substance may be transported across the stomach. The physiologically active substance may be stable and not degrade in the harsh gastric acid environment. To help protect the physiologically active substance, the physiologically active substance is mixed with the carrier. The carrier may be a liquid insoluble in the gastric acid of the stomach. The physiologically active substance may be soluble in the carrier. The mucoadhesive compound may be used to promote adsorption of the physiologically active substance to the lining of the stomach. The permeation enhancer may facilitate the transport of the physiologically active substance across the wall of the stomach.
A self powered device for the continuous and controlled delivery of an agent over a prolonged period of time to an agent receptor is disclosed. The device is comprised of a pressure distendable receptacle formed of an elastic material, with the receptacle communicating with a discharge port having a flow resistive agent metering means for releasing agent in fluid form. The receptacle has an entry port providing access to its interior with the port having a sealing means. The receptacle is dimensioned for insertion in its collapsed state into a receptor site and it is expandably responsive to an applied pressure induced by forced infusion of agent through the port after the receptacle is in the receptor. The infusion of agent establishes an internal stress in the elastic material with the material maintaining as a result of the stress a substantially constant internal pressure in the receptacle throughout the discharge of the agent from the receptacle. The receptacle is adapted for easy removal from the agent receptor after the administration of agent.
Subjects receive 10 weeks of topiramate with a dosage starting at 25 mg per day. At week two (quit date) subjects increase to 50 mg/day and gradually increase to 200 mg/day and one week taper for a total time of 10 weeks. On the quit date (after 2 weeks of Topiramate medication use), subjects also use 21 mg patch for 7 weeks and on week 8 subjects received 14 mg/day for 3 days then 7 mg for 4 days.
This paper describes the Wellness in Chronic Care (WCC) model, an innovative integrative clinical intervention method aimed at helping social workers manage the care of patients living with chronic illnesses and their families. The goal is to propose appropriate clinical responses to the changing reality of the health system. This new reality poses new challenges that require caregivers (social work practitioners and family members) to develop suitable skills and expertise. The intervention method we developed offers a new paradigm that entails partnership and the need to assume responsibility in decision-making while coping with the illness over time. The intervention provides practical tools and methods for coping and managing the illness. These factors have contributed to building a specifically tailored intervention program for patient and family care to achieve an effective and meaningful wellbeing. An assessment of the training program of the intervention model and its implementation is presented. The model was found to be essential yet some found it difficult to make the needed changes.
Background: High-dose vasopressors maintain blood pressure during septic shock but may adversely reduce microcirculation in vital organs. We assessed the effect of high-dose norepinephrine and vasopressin on the microcirculation of the brain, tongue, liver, and kidney during endotoxic shock using near-infrared spectroscopy (NIRS). Methods: Thirteen pigs (24.5 ± 1.8 kg) were anesthetized, and an NIRS probe was attached directly to each organ. Approximately 0.2, 0.5, 1, and 2 μg/kg/min of norepinephrine were administered in a stepwise manner, followed by 0.5, 1, 2, and 5 μg/kg/min of sodium nitroprusside in normal condition. Moreover, 1 μg/kg/h of lipopolysaccharide was administered continuously after 100 μg bolus to create endotoxic shock and after 1,000 mL of crystalloid infusion and high-dose norepinephrine (2, 5, 10, and 20 μg/kg/min) and vasopressin (0.6, 1.5, 3, and 6 U/min) were administered in a stepwise manner. The relationship between the MAP and each tissue oxygenation index (TOI) during vasopressor infusion was evaluated. Results: Three pigs died after receiving lipopolysaccharides, and 10 were analyzed. An increase of >20% from the baseline MAP induced by high-dose norepinephrine during endotoxic shock reduced the TOI in all organs except the liver. The elevation of MAP to baseline with vasopressin alone increased the kidney and liver TOIs and decreased the tongue TOI. Conclusion: Forced blood pressure elevation with high-dose norepinephrine during endotoxic shock decreased the microcirculation of vital organs, especially the kidney. Cerebral TOI may be useful for identifying the upper limit of blood pressure, at which norepinephrine impairs microcirculation.
FIELD: medicine, pharmacy. SUBSTANCE: proposed medicinal form of acetylsalicylic acid has acetylsalicylic acid, citric acid, succinic acid, alkaline metal carbonate and/or hydrocarbonate and an additional substance: water-soluble sugar taken from the order: lactose, glucose, sucrose taken at the definite ratio of components in mas. p. p. Also, composition can contain additionally ascorbic acid; binding agent: polyvinylpyrrolidone (molecular mass is 10000-40000 Da) or carboxymethylcellulose sodium; slipping substance: fumaric acid or benzoate sodium; sweetening agent - saccharin, saccharinate sodium or aspartam, and an aromatic principle also. Invention provides a possibility to use medicinal form of acetylsalicylic acid by patients suffering with different forms of diabetes mellitus, hypertension and other pathological states requiring limitation of sodium ions usage. EFFECT: improved quality of drug. 7 cl, 3 tbl, 20 ex
After consent, a maternal sample of whole blood will be obtained for DNA isolation. Investigators will collect plasma samples at 4 time points on all participants. These will be done at baseline (pre-dose), and 0.5-2 hours, 4-6 hours, and 22-24 hours after the first dose of BMZ is administered. Investigators will obtain serum for estriol measurement on all participants before or within 2 hours of antenatal corticosteroid administration and about 24 hours after each dose is given (betamethasone is administered as 2 doses 24 hours apart). Investigators will obtain a saliva sample for measurement of estriol at the same times. Participants will be offered optional participation in a more detailed PK portion of the study. Participants who consent to this part of the study will have additional plasma samples obtained at a schedule of sampling of approximately 10-15 hours after the first dose and then 6-8 hours, 24, and 48 hours after the 2nd dose. One sample will be collected at each of these times. At the time of delivery, umbilical cord blood will be collected before being discarded for DNA, serum and plasma. Four placenta sections will be collected. A maternal blood sample will also be obtained for serum and plasma. If the investigators are unable to obtain umbilical cord blood, a buccal swab will be collected from the baby for DNA extraction. A chart review will be done on the infant within 30 days of birth to review and record neonatal outcomes.
A novel phospholipid - protein - lipopolysaccharide complex which is water-soluble is obtained by growing a lysine requiring mutant of a Gram-negative species of bacteria in a sub-optimal concentration of lysine, obtaining a cell-free liquid from the resulting culture, precipitating the complex from this liquid by dissolving therein a polar, substantially water-immiscible halogenated hydrocarbon, separating the precipitate and removing the halogenated hydrocarbon therefrom.  Suitably, Escherichia coli is grown for 16-48 hours at 25-40 DEG  C. in lysine of 20-500 mg/l concentration, at pH 5-8, under conditions of high aeration.  The complex may be purified by conventional means such as repeated precipitation, ion-exchange, dialysis, gel-filtration or sedimentation, and may additionally be purified with MgSO4 causing precipitation, followed by dissolution in EDTA, dialysis against EDTA, and finally against water.  Suitable halogenated hydrocarbons are CHCl3, CH2Cl2 and CHCl=CCl2. The phospholipid in the complex is mainly phosphatidylethanolamine.  The lipopolysaccharide can be obtained from the complex by hydrolysis using aqueous phenol.
The baseline cohort (gathered in the years 2012-2015) is a random sample selected through the National Civil Registration system among people living in 10 municipalities in the western part of greater Copenhagen, Denmark, ages 18 to 76 years. The baseline cohort constitutes data from self-reported questionnaires (n=7,493) and diagnostic interviews data (n=1,590).
To analyse the risk factors and healing factors of pharyngocutaneous fistula (PCF) in patients with laryngeal cancer after total laryngectomy, and to explore the relevant epidemiology. A retrospective analysis was conducted on laryngeal cancer patients who underwent total laryngectomy in our hospital from January 2010 to December 2022. The 349 patients included in the study were divided into a PCF group of 79 and a non-PCF group of 270. Perform one-way analysis of variance and multivariate logistic analysis on various data of patients included in the statistics, and analyse the risk factors and healing factors of PCF. Smoking, history of radiation therapy for laryngeal cancer, history of chemotherapy for laryngeal cancer, tumour location (larynx, pharynx, oesophagus), preoperative albumin, postoperative proteinaemia, <99 haemoglobin, postoperative haemoglobin, postoperative C-reactive protein (CRP) level are the risk factors for PCF. Also, radiation therapy and postoperative proteinaemia were the main reasons for preventing PCF healing. Smoking history, laryngeal cancer, radiation therapy, albumin, haemoglobin and CRP are risk factors for postoperative PCF after total laryngectomy, while radiation therapy and postoperative hypoalbuminaemia are key factors affecting PCF healing.
The utility model relates to a meridian therapeutic band for internal medicine in a hospital, which comprises a base band, a Chinese medical patch and four magnetic powder strips. The base band is a basic band, the whole structure of the base band is of a rectangular shape, the four sides of the base band respectively adopt a bonding adhesive tape near the edges thereof, the Chinese medical patch is arranged in the middle of the base band, and the four magnetic powder strips are vertically arranged on the Chinese medical patch. The Chinese medical patch is prepared with 2g of galangal, 3g of Chinese mugwort leaf, 1g of elecampane, 1g of cinnamon, 1g of fructus amomi, 3g of flos caryophylli, 2g of rhizoma sparganii, 3g of curcuma zedoary, 4g of safflower and 3g of magnetite. The preparation of the Chinese medical patch comprises the following steps: grinding the raw materials into powder, preparing an ointment according to the adhesive plaster process, and spreading the ointment in the middle of the base band, thereby obtaining the Chinese medical patch. The four magnetic powder strips are arranged between the Chinese medical patch and the base band. The utility model has the advantages of simple overall structure and convenient operation and use. When the internal medical patient suffers from the pain for unknown reasons, the utility model can be applied on the navel of the patient for treatment, with the central magnetic powder strips aligned with the two sides of the navel.
<P>PROBLEM TO BE SOLVED: To provide a stent containing medicine in a surface coating neither increasing the wall thickness of the stent nor having an adverse effect on mechanical expansion characteristics.  <P>SOLUTION: An expandable medical device 10 includes a plurality of elongated struts 18 forming a substantially cylindrical device 12 expandable from a first diameter to a second diameter. A plurality of different beneficial agents are loaded into different openings 30a, 30b within the struts and delivered to the tissue. For treatment of different diseases, different agents may be used from the same drug delivery device. In addition, anti-thrombotic agents may be affixed to at least a portion of the surfaces of the medical device for the prevention of sub-acute thrombosis.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Infusion Tranexamic acid on study subjects. They will be randomized to receive an infusion of the standard dose of Tranexamic acid (10mg/kg) One dose will be given by the bedside nurse within 60 minutes prior to surgery and a second dose will be given at wound closure. Infusion will be given along with standard preoperative and operative infusion; no additional infusion will be necessary.
In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
PROBLEM TO BE SOLVED: To obtain a medicinal composition making absorption from an alimentary canal effective by forming an active ingredient into a solid dispersoid. SOLUTION: This medicinal composition is obtained by dissolving 2-(4- carboxypiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinozoline sodium and a polymer substance (e.g. hydroxypropylcellulose acetate) in a solvent (e.g. water-ethanol) and evaporating and drying the solvent to afford a solid dispersoid. The solid dispersoid can be prepared in granules, tablets, etc., by powdering and sieving the dispersoid and, as necessary, mixing with other substances. The medicinal composition can also be obtained by molding the composition and a polymer using a stirring compression type extruding glanulator. The water-soluble polymer is used in an amount of >=4 pts.wt. based on 1 pts.wt. of the compound. The medicinal composition exhibits high solubility and quick dissolving rate.
The experimental group will receive added PPT to the conventional physiotherapy. PPT will be applied by means of a neuro-orthopaedic medical device ("Posturomed®", see section 3.2). The "Posturomed" allows adaptive oscillation in the horizontal plane. Therapy instructions advise seven stages of difficulty. In all stages the patient is asked to provoke oscillation by stepping on site. After three steps, the patient must stand still on one leg for 2 seconds before he or she repeats the steps. Difficulty is increased by a) decreasing the damping through release of the breaks and b) through added juggling of a ball during the motor task (dual-task and divided attention). The next stage is reached once stabilisation in the previous stage is secured.
The patients of early group will be performed water swallowing test at bedside after 2 hours of extubation. Before performing the Water Swallow Test, the patient must be evaluated for readiness.This interventional group of patients will be initiated with sips of water (warm or cold as patient prefers) at 2 hours of extubation (post-operative day 0) followed by clear liquid diet (tea, clear juice/ soup, gelatin) at 4 hours. If well tolerated, then slowly progress to a full liquid and solid diet as the patient preferred pace.
Participants in this group will have been treated with alendronate for at least 1 year prior to study entry. Upon study entry, they will receive a cyclical regimen of teriparatide, in addition to alendronate. Teriparatide will be administered subcutaneously in 20-mcg doses daily for 3 months. They will receive no teriparatide for the following 3 months, and then teriparatide treatment will continue for the 3 months after that. This schedule will continue for 24 months with an aption to all participants to continue cyclic teriparatide for another 24 months. Biopsies will be performed at Week 7 or Month 7.5.
The patient will be taken care by the physician SMUR or home emergency. Upon acceptance of participation in the study, the clock will be started at the time of the establishment of the face mask. The medical air is administered for 30 minutes and an opioid titration is started 10 minutes after the introduction of gas, unless the patient expresses pain score EN \<3/10.
Abstract of the Disclosure B-cell lymphomas express surface immunoglobulin (immunoglobulin) containing unique idiotypic (idiotype) determinants which may be exploited as tumor specific markers. Applicant has produced murine monoclonal antibodies (MAbs) reactive with the idiotype marker derived from 67 patients with low grade, follicular, small cleaved cell lymphoma. Out of 199 monoclonal antibodies, 47 (24%) were found to react with pooled normal human serum immunoglobulin in concentrations ranging from 0.6 µg/ml to 160 µg/ml. Of these 40 monoclonal antibodies, 90% cross-reacted with idiotype present in normal serum in levels <50 µg/ml. Thirty-two of these anti-idiotypes were directed against a shared idiotope expressed on another patient's lymphoma cells. The frequency of shared idiotope expression defined by each antibody ranged from 0.26% to 3.9% of the B-cell lymphomas tested. A panel of five anti-idiotype antibodies reacted with 80% of AIDS associated lymphomas. Based on the reactivity with these monoclonal antibodies, tumors could be grouped into distinct families. In aggregate, these 32 monoclonal antibodies reacted with a total of 108 of 332 B cell lymphoma cases (32.5%), including 35 of 116 follicular, small cleaved cell lymphomas (30%). Many of these anti-shared idiotopes reacted with more than one histopathologic subtype of lymphoma Anti-idiotypes have been used in B-cell lymphoma diagnosis and therapy. Moreover, applicant has discovered at least seven anti-shared idiotype antibodies that cross react with autoantibodies, e.g., 16.6 and RF. The development of a library of anti-idiotypes reactive with shared idiotopes should facilitate these clinical studies by obviating the need to develop a customized hybridoma for each patient.
The virtual intervention arm will be an 8-week program plus four week short maintenance period but will include two separate 1 hour sessions per week. This includes: 1) 60 minutes of virtual, group-based, synchronous exercise over a virtual secure platform; and, 2) A separate 60 min virtual synchronous education session provided on a separate day (to prevent virtual fatigue). 3) Encouragement to participate in a home program the other days of the week, striving for the recommended 90 min of moderate to vigorous aerobic exercise and 2 days of week or resistance exercise. The virtual intervention group will combine participants across both study locations and run sessions when sufficient numbers are recruited. Self-management education content will be unchanged to the in-person sessions but conducted over a virtual platform (i.e., videoconferencing) with participants also attending virtually.
INTRODUCTION: We examined the gut microbiota of travellers returning from tropical areas with and without traveller's diarrhoea (TD) and its association with faecal lipocalin-2 (LCN2) levels.
METHODS: Participants were recruited at the Hospital Clinic of Barcelona, Spain, and a single stool sample was collected from each individual to perform the diagnostic of the etiological agent causing gastrointestinal symptoms as well as to measure levels of faecal LCN2 as a biomarker of gut inflammation. We also characterised the composition of the gut microbiota by sequencing the region V3-V4 from the 16S rRNA gene, and assessed its relation with the clinical presentation of TD and LCN2 levels using a combination of conventional statistical tests and unsupervised machine learning approaches.
RESULTS: Among 61 participants, 45 had TD, with 40% having identifiable etiological agents. Surprisingly, LCN2 levels were similar across groups, suggesting gut inflammation occurs without clinical TD symptoms. Differential abundance (DA) testing highlighted a microbial profile tied to high LCN2 levels, marked by increased Proteobacteria and Escherichia-Shigella, and decreased Firmicutes, notably Oscillospiraceae. UMAP analysis confirmed this profile's association, revealing distinct clusters based on LCN2 levels. The study underscores the discriminatory power of UMAP in capturing meaningful microbial patterns related to clinical variables. No relevant differences in the gut microbiota composition were found between travellers with or without TD.
DISCUSSION: The findings suggest a correlation between gut microbiome and LCN2 levels during travel, emphasising the need for further research to discern the nature of this relationship.
Dose Selection 

GEODON Capsules should be administered at an initial daily dose of 20 mg twice daily with food. In some patients, daily dosage may subsequently be adjusted on the basis of individual clinical status up to 80 mg twice daily. Dosage adjustments, if indicated, should generally occur at intervals of not less than 2 days, as steady-state is achieved within 1 to 3 days. In order to ensure use of the lowest effective dose, patients should ordinarily be observed for improvement for several weeks before upward dosage adjustment. 

Efficacy in schizophrenia was demonstrated in a dose range of 20 mg to 100 mg twice daily in short-term, placebo-controlled clinical trials. There were trends toward dose response within the range of 20 mg to 80 mg twice daily, but results were not consistent. An increase to a dose greater than 80 mg twice daily is not generally recommended. The safety of doses above 100 mg twice daily has not been systematically evaluated in clinical trials [see Clinical Studies (14.1)].